ドイハラ　ヒロヨシ   Hiroyoshi Doihara   土井原　博義    所属   川崎医科大学  医学部 臨床医学　総合外科学    職種   特任教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
掲載誌名	正式名：Cancer chemotherapy and pharmacology 略　 称：Cancer Chemother Pharmacol ISSNコード：14320843/03445704
掲載区分	国外
巻・号・頁	81(2),pp.269-275
著者・共著者	Shien Tadahiko, Doihara Hiroyoshi, Sato Nobuaki, Anan Keisei, Komaki Kansei, Miyauchi Keisuke, Yanagita Yasuhiro, Fujisawa Tomomi, Mitsuyama Shoshu, Kanbayashi Chizuko, Kusama Mikihiro, Kimura Morihiko, Jinno Hiromitsu, Sano Muneaki, Ikeda Tadashi
発行年月	2018/02
概要	A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four postmenopausal breast cancer patients [ER positive, HER2 negative, T1-2, node metastases (n = 0-3), M0] who had undergone curative resection were enrolled. They were randomized to receive either TOR 40 mg/day or LET 2.5 mg/day as adjuvant hormone therapy. Serum lipids and bone markers were measured prior to, and again at 6, 12, and 24 months after initiation of treatment. Changes in serum lipids and bone markers were compared. Serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were decreased compared with the baseline values at 6 months in 6.5 and 14.0% of patients, respectively, receiving TOR. Lipid levels did not change in patients administered LET. Significant differences were observed in TC and LDL-C between the two groups at 12 and 24 months. In the TOR group, serum bone-specific alkaline phosphatase (BAP) was decreased by 25.0% at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6% at 6 months, and these reductions were maintained for at least 24 months. In contrast, in the LET group, serum BAP did not change and NTx was increased by 16.0% at 6 months and by 18.6% at 24 months, as compared with the baseline.TOR and LET exert different effects on serum lipid profiles and bone metabolism markers. The effects of TOR, as adjuvant hormone therapy, on both lipids and bone metabolism in postmenopausal breast cancer patients are superior to those of LET.
DOI	10.1007/s00280-017-3491-6
PMID	29196963